Early work in germ-free rodents highlighted the gut microbiota's importance in 20 metabolic disease, including Type II Diabetes Mellitus (T2DM) and obesity. Glucagon-21 like peptide-1 (GLP-1) is an incretin secreted by enteroendocrine L-cells lining the 22 gastrointestinal epithelium. GLP-1 has important functions including promoting insulin 23 secretion, insulin sensitivity, and β-cell mass, while inhibiting gastric emptying and 24 appetite. We set out to elucidate how the microbiota can modulate GLP-1 secretion, 25 with the goal to identify microbial strains with GLP-1 stimulatory activity as a metabolic 26 disease therapeutic. Over 1500 human-derived strains were isolated from fecal, breast 27 milk, and colon and intestinal biopsy samples from healthy individuals. In vitro screening 28 for GLP-1 modulation was performed by incubating bacterial cell-free supernatants with 29 NCI H716 human L-cells. Approximately 45 strains capable of increasing GLP-1 levels, 30 measured by ELISA, were discovered. Interestingly, all positive strains were identified 31 as Staphylococcus epidermidis by 16S rRNA sequencing. Non-GLP-1 stimulatory S. 32 epidermidis strains were also identified. Mass spectrometry analysis identified a 3 kDa 33 peptide, termed GLP-1 stimulating peptide (GspA), present in GLP-1 positive but absent 34 in GLP-1 neutral S. epidermidis. Studies in human L-cells and intestinal enteroids 35 demonstrated that GspA alone is sufficient to enhance GLP-1 secretion. When 36 administered in high-fat-fed mice, GspA-producing S. epidermidis significantly reduced 37 markers associated with obesity and T2DM, including adiposity and hyperinsulinemia. 38 Further characterization of GspA suggests a GLP-1 stimulatory action via calcium 39 signaling. The presented results identify a novel host-microbe interaction which may 40 3 ultimately lead to the development of a microbial peptide-based therapeutic for obesity 41 and T2DM. 42 43 Importance 44
Introduction 56
Metabolic disorders, including Type 2 Diabetes Mellitus (T2DM) and obesity, 57 pose a serious public health concern both nationally and globally. According to the 58 Centers for Disease Control and Prevention (CDC), 9.4% of the population of the United 59
States has Diabetes, including 25.2% of those aged 65 years or older (1). Obesity is 60 also a major health concern, with more than one-third of American adults considered 61 obese (2). Current treatment approaches, including intensive lifestyle modifications, diet 62 intervention, and pharmacologics, have proven unsuccessful in controlling the global 63 increase of metabolic disorders. Therefore, a novel approach to combat metabolic 64 disorders is needed. 65 A number of research groups have recently demonstrated the role of the human 66 gut microbiota in metabolism and metabolic disease, leading to the attempt to develop 67 microbial therapeutics. Backhed et al. initially spearheaded this research; using germ-68 free rodents, it was demonstrated that when the microbiota of conventionally raised 69 animals was transplanted into germ-free rodents, the latter developed an increase in 70 adiposity and insulin resistance (3). Studies by a number of different groups also 71 demonstrated the importance of the microbiota in metabolism. A recent case report 72 involving a woman undergoing a fecal microbiota transplant (FMT) for a Clostridium 73 difficile infection (CDI) proposed that the donor's "obese phenotype" was transferred to 74 the patient, suggesting that the rodent observations also apply to humans (4). 75
Specifically, the gut microbiota has been shown to play an important role in gut 76 hormone modulation, including GLP-1. Administration of prebiotics, non-digestible food 77 ingredients that stimulate the growth of specific organisms of the microbiota, increased 78 GLP-1 concentrations, correlating with appetite, fat mass, and hepatic insulin resistance 79 (5) . Samuel et al. demonstrated that n-butyrate, a short-chain fatty acid originating from 80 the gut microbiota, increased GLP-1 production (6). As well, Yadav et al. demonstrated 81 an increase in GLP-1 levels in mice following administration of a butyrate-producing 82 probiotic (7) . Everard et al. showed that the abundance of Akkermansia muciniphila is 83 correlated with increased intestinal levels of 2-oleoylglycerol (2-OG), which stimulates 84 GLP-1 secretion from intestinal L cells in type 2 diabetic mice (8). Specifically, 2-OG has 85 been shown to be an agonist of GPR119, a receptor that plays a key role in promoting 86 GLP-1 release in humans. Although promising results have been observed for microbial 87 therapeutics, a successful therapeutic capable of combatting metabolic disorders, 88 particularly T2DM and obesity, has yet to be developed. Moreover, the exact role of the 89 microbiota on GLP-1 modulation remains to be elucidated and investigated as a 90 therapeutic target. The presented work aims to identify human-derived bacterial strains 91 capable of stimulating GLP-1 secretion, with the goal of developing a metabolic disease 92 therapeutic. 93 94
Methods 95
Bacterial strain isolation 96 Strains JA1, JB1, JD11, and JA8 were isolated from human breast milk from a 97 female who had been lactating for four months. Prior to collection, the surface of the 98 areola was sterilized with 70% (v/v) ethanol wipes. Milk was collected using a freshly-99 sterilized adapter and bottle. After collecting 1 mL, the collection bottle was replaced 100 with a new, sterile bottle and collection continued until natural cessation of milk flow. 101
This latter volume was used for isolation. Bacteria were concentrated from milk by 102 centrifugation at 1789 X g for 10 min, resuspended in a small volume of supernatant 103 (whey fraction), and spread plate onto BHIS (JA1, JB1, JA8) or Hyp1 (JD11) plates and 104 incubated at 37°C in a hypoxic chamber with atmosphere of 2% O 2 , 5% CO 2 , 93% N 2 . 105
Individual colonies were re-streaked twice on the same agar medium (BHIS or Hyp1) to 106 ensure homogeneity. The majority of colonies from the second re-streaked plate were 107 scraped into liquid medium amended with 15% (v/v) glycerol and stored at -80°C. 108
109

16S rRNA sequencing of isolates 110
To identify the bacterial isolates, bacteria were streaked on GM17 agar plates 111 from frozen stock and incubated at 37°C for 1-2 days. Bacterial colony mass was then 112 resuspended in 100 µL of water and transferred to sterile bead beating tubes and 113 homogenized for 2 min in a mini-beadbeater-96 (Biospec Products). Tubes were 114 centrifuged at 8000 xg for 30 secs and supernatants were used for 16S rRNA gene 115 PCR amplification. The final 25 µL PCR reactions contained 1 µL of template, 1X 116 Physion High Fidelity Buffer (New England Biolabs), 200 µM dNTPs (Promega), 10 nM 117 primers (8F and 1492R) and 0.225 units of Phusion DNA Polymerase (New England 118 Biolabs). The amplification cycle consisted of an initial denaturation at 98°C for 30s, 119 followed by 26 cycles of 10 sec at 98°C, 20 secs at 51°C, and 1 min at 72°C. 120 Amplification was verified by agarose gel electrophoresis. For sample cleanup, 1 µL of 121 Exo-SAP-IT (ThermoFisher) was added to 2.5 µL of PCR product and incubated at 122 37°C for 15 min followed by a 15 min incubation at 80°C to inactivate the enzyme. The 123 product was cooled, and 5.5 µL of water and 1 µL of 10 µM 1492R primer were added 124 and sent to Genewiz for sequencing. 125 126 Bacterial growth and preparation of cell-free supernatants 127
Bacterial isolates were streaked from frozen glycerol stocks onto GM17 agar 128 plates and incubated anaerobically overnight at 37°C. One colony was inoculated into 5 129 mL of GM17 broth and incubated overnight at 37°C followed by one more subculture 130 into GM17 broth, and incubated overnight at 37°C. Once grown, bacterial cultures were 131 centrifuged at 5000 x g for 20 min. Supernatants were collected and lyophilized 132 (Labconco Freezone), followed by storage at -80°C until used for subsequent assays. 133
For size fractionation studies, bacterial cell-free supernatants were separated by size 134 using centrifugal filter units (Amicon). 
Mouse studies 160
To investigate whether a GLP-1 stimulating bacterial strain identified in vitro 161 could have an effect on metabolic disease markers in vivo, we performed a mouse 162 study. We used 8 week old female C57BL/6 humanized microbiota mice established by 163 Collins et al. (9) . Mice were housed three per cage in a room with controlled 164 temperature, humidity, and alternating light and dark cycle (12:12 h light/dark cycle). 165
The two diets were obtained from Research Diets (New Jersey, USA): high fat diet 166 (D12492) containing 60 kcal% fat and control diet (D12450B) containing 10 kcal% fat. 167
Mice were randomized by mass into three groups (n = 6): 1) normal fat diet treated with 168 vehicle (GM17 culture media), 2) high fat diet treated with vehicle, and 3) high fat diet 169 treated with 2 x 10 8 cells/mouse S. epidermidis JA1 culture. Mice were allowed free 170 access to food and water. The experiment lasted for 16 weeks with treatments 171 administered five times a week by intragastric gavage. Food intake and body mass 172 were monitored twice a week. Serum was collected every two weeks following 6 h 173 fasted animals by venous tail bleed for glucose and insulin measurements. Oral glucose 174 tolerance tests (2 g glucose/kg animal mass) were performed every four weeks. Mice 175 were euthanized after a 6 h fast by carbon dioxide asphyxiation and blood was drawn Screening of a human-derived microbial library for regulation of the incretin hormone 267
GLP-1 268
In order to identify bacterial strains capable of eliciting GLP-1 secretion, 1500 269 microbial strains were screened using the GLP-1 secreting human cell line NCI H716 270 (11). Cell-free supernatants of each microbe were prepared and applied to monolayers 271 of NCI-H716 cells for 2 hours. GLP-1 secreted into the medium was analyzed by ELISA. 272
Of the 1500 strains that were screened, the vast majority (>1400) had no positive or 273 negative impact on GLP-1 secretion. We identified 45 isolates that showed increased 274 GLP-1 secretion similar to or above stimulation of GLP-1 with the positive control 275 phorbol 12-myristate 13-acetate (PMA). We also identified 25 strains that dramatically 276 reduced the level of secreted GLP-1; these strains were not further characterized as 277 part of this study. 278
16S rRNA sequencing of all 45 stimulatory strains identified them as S. 279 epidermidis isolates. We originally isolated most of these strains from either breast milk 280 or fecal samples from healthy human volunteers. To further characterize the impact of 281 S. epidermidis strains on GLP-1 secretion, we incubated cell-free supernatants from two 282 of the stimulatory strains with the highest activity, S. epidermidis JA1 and JA8. 
S. epidermidis JA1 reduces markers of metabolic disease 301
Following identification of JA1 as the strongest stimulator of GLP-1 secretion in 302 vitro, we investigated its ability to modulate markers of metabolic disease during a 16-303
week study in a high-fat model of disease. Mice were placed on a high-fat diet and 304 gavaged either with S. epidermidis JA1 or GM17 medium as a negative control 5 times 305 per week. Administration of S. epidermidis JA1 to HFD-fed mice for 16 weeks reduced 306 markers of obesity, body mass, and adiposity compared to the GM17 medium control. 307
Mice fed a HFD gained significantly more mass than mice on the conventional diet 308 during the course of the study, administration of JA1 significantly reduced animal mass 309 in mice fed a HFD (Figure 2A ). This significant difference was noted as of day 42 (p < 310 0.05), and at every time point for the rest of the study, with animal percent body mass of 311 122.6 ± 13.0 % and 115.9 ± 4.7 % for the HFD-fed mice and HFD-fed mice 312 administered JA1, respectively. 313
Since we hypothesized that S. epidermidis JA1 administration enhances the 314 secretion of GLP-1, a satiety hormone, we also monitored food consumption throughout 315 the 16 week study (Figure 2B) . The average food consumption for the HFD-fed mice 316 was 13.0 ± 1.15 g/week compared to 12.09 ± 0.89 g/week for the HFD-fed mice 317 administered S. epidermidis JA1 (p = 0.0082), demonstrating that S. epidermidis JA1 318 reduced food intake. To assess adiposity, the gonadal adipose tissue was measured at 319 the end of the study (Figure 2C) . Mice fed a HFD had significantly more (p < 0.0001) 320 adipose tissue mass (1.72 ± 0.59 g) than their LFD-fed counterparts (0.28 ± 0.10 g). 321
Administration of S. epidermidis JA1 significantly reduced (p = 0.004) the levels of 322 adipose tissue mass (0.83 ± 0.34 g). S. epidermidis JA1 administration in HFD-mice 323 reduced the levels of fasted hyperinsulinemia. Feeding with a HFD (0.75 ± 0.06 ng/mL) 324 significantly elevated (p < 0.0001) the levels of fasted serum insulin as compared to 325 mice administered the LFD (0.24 ± 0.12 ng/mL) (Figure 3) . Administration of S. 326 epidermidis JA1 (0.48 ± 0.06 ng/mL) significantly reduced (p = 0.0004) fasted serum 327 insulin levels in HFD-fed mice. Taken together, this data suggests potential for the 328 modulation of Type II Diabetes and obesity markers by S. epidermidis JA1. 329 330
Identifying the microbial-derived compound responsible for GLP-1 stimulatory activity 331
To better characterize the bacterial component responsible for GLP-1 secretion 332 in vitro and for metabolic disease marker modulation in vivo, we performed size 333 fractionation studies using Amicon centrifuge filtration tubes. We used two GLP-1 334 stimulatory S. epidermidis strains, JA1 and the S. epidermidis type strain ATCC 12228, 335 for these studies. As shown in Figure 4 , the vast majority of the GLP-1 stimulatory 336 activity was present in the greater than 100 kDa fraction of the bacterial supernatants 337 ATCC 12228 compared to 482 ± 20 pM in the media control). We also determined that 343 the bacterial component is completely resistant to heat exposure (100°C for 30 min) and 344 Proteinase K treatment (50 µg/mL for 1 h). 345
To further identify the component responsible for the activity, we analyzed 346 trypsinized bacterial supernatants by LC/MS using an Orbitrap Fusion mass 347 spectrometer equipped with an Easy Nanospray HPLC system. Analysis of the GLP-1 348 stimulatory and neutral S. epidermidis supernatants identified 269 protein groups, of 349 which none were detected in the GM17 medium control. A secreted peptide, with amino 350 acid sequence MAADIISTIGDLVKWIIDTVNKFKK and a size of 3 kDa was detected in 351 the form of two trypsin-digested peptides (Suppl. Fig 1) in the GLP-1 stimulatory S. 
GspA can modulate intracellular calcium levels 374
We hypothesized that GspA may be stimulating the release of GLP-1 by altering 375 calcium signalling. To investigate this possibility, we used HEK293 cells stably 376 expressing a genetically-encoded calcium sensor GCaMP6S, which exhibits increased 377 green fluorescence upon an increase in cytosolic calcium levels (14) . Using the 378 HEK293-GCaMP6S cell line, we found that treatment with 5 µM GspA induced a strong 379 increase in cytoplasmic calcium, as shown by the levels of green fluorescence signal 380 following exposure to the peptide (Figure 6A) . The increase in cytosolic calcium 381 induced by GspA was significantly greater that induced by PsmD, which highlights the 382 functional differences between these two peptides. Extracellular calcium was important 383 for the GspA-induced increased in cytoplasmic calcium because EDTA chelation of 384 extracellular calcium significantly reduced the calcium flux (Figure 6B) . Calcium influx 385 through the plasma membrane would induce an increase in the membrane voltage, 386 depolarizing the membrane potential. Thus, we performed current clamp 387 electrophysiology studies to measure changes in the membrane voltage upon treatment 388 with PsmD or GspA. We found that GspA induced a rapid and significant depolarization 389 of NCI H716 cells, but PsmD treatment did not alter the membrane potential ( Figure  390   6C) . Taken together, this data suggests that GspA may be stimulating GLP-1 release 391 via a calcium-dependent mechanism. 392 393
GspA's effect on the release of other enteroendocrine cell molecules 394
We further wanted to investigate the specificity of GspA's activity and its ability to 395 stimulate the release of other enteroendocrine cell molecules. We have developed a 396 novel human enteroid model using overexpression of Neurogenin-3 (a transcription 397 factor that stimulates enteroendocrine cell differentiation, giving rise to higher 398 enteroendocrine cell counts and GLP-1 levels). Using this model with GspA, there was 399 no visible effect on cell viability, as measured by a resazurin-based assay (Figure 7A) , 400 indicating that GspA is having no toxic impact on cells. As with validation of the GLUTag 401 and NCI H716 GLP-1 data, GspA did indeed enhance GLP-1 secretion in the enteroid 402 model (Figure 7B) . Interestingly, GspA exposure also stimulated the release of another 403 gastrointestinal molecule, serotonin (Figure 7C) . Conversely, GspA did not stimulate 404 the release of glucagon (Figure 7D) , peptide YY (Figure 7E) , or gastric inhibitory 405 peptide (Figure 7F) . Taken together, this data suggests specificity in GspA's 406 mechanism of action for the release of gastrointestinal hormones, not simply as a non-407 specific pore-forming complex. 408
409
Discussion 410
Regulation of intestinal hormones and physiology by microbes and microbial 411 metabolites offers a novel approach to guide intestinal and systemic health. We 412 targeted the incretin hormone GLP-1 due to its well-established impact on satiety and 413 hyperglycemia, described in detail in a recent review (15). Indeed, treatment of type 2 414 diabetes with GLP-1 receptor agonists, including FDA-approved exenatide and 415 liraglutide, have demonstrated significant reductions in hyperglycemia, haemoglobin 416 A1c, and body weight (16). Previous studies have identified the gut microbiota as a key 417 component in the regulation of GLP-1 secretion, although the mechanisms of action and 418 organisms responsible for this activity have not been well-defined (17) . In this work, we 419 initially aimed to identify human-derived microbial strains capable of promoting GLP-1 420 secretion. Despite extensive screening of over 1500 strains, we were able to 421 demonstrate significant specificity for GLP-1 release by identifying only strains of S. 422 epidermidis, isolated from either breast milk or fecal samples of healthy donors, that 423 possess this activity. 424 S. epidermidis is an indigenous member of the skin microbiota as well as the 425 intestinal microbiota of infants and plays a key role for the proper education of the 426 immune system at the skin surface (18, 19) . However, much less is known about how S. 427 epidermidis impacts the intestinal tract and gut function. Much of the work on S. 428 epidermidis has focused on its role as a pathogen, often identified as a cause of 429 catheter acquired infections. Thus S. epidermidis has traditionally been thought of as an 430 opportunistic pathogen or a "pathobiont". However, more recent work has suggested 431 that S. epidermidis, unlike its more sinister cousin S. aureus, does not possess bona 432 fide virulence factors or toxins and has been referred to as an "accidental pathogen" 433 (20) . 434
The strongest GLP-1 stimulator strain in vitro, S. epidermidis JA1, a human 435 breast-milk isolate, reduced weight gain and fat accumulation in HFD-fed mice over the 436 course of a long-term 16-week study. The reduction in weight and adiposity was 437 associated with a marked decrease in food intake, a function controlled by secretion of 438 GLP-1. In our humanized microbiota mice we did not observe a statistically significant 439 increase in fasted glycemia between the high-fat and control diet mice and thus we 440 cannot assess the role of S. epidermidis JA1 on type 2 diabetes (although we note the 441 S. epidermidis group trended toward a lower fasted glycemia, as seen in the control 442 mice (Supp. Fig 2) ). Nevertheless, the observed resistance to HFD-induced 443 hyperglycemia by the humanized microbiota mice that is typically observed in 444 conventional C57BL/6 mice is of interest for further investigations. Regardless, we did 445 observe a significant change in the fasted serum insulin levels with the S. epidermidis 446 group, dramatically lowering fasted insulin levels. This indicates that S. epidermidis 447 treatment impacts hyperinsulinemia, a key driver of insulin resistance, metabolic 448 syndrome, and other disorders including cardiomyopathy (21). Unfortunately we were 449 unsuccessful, despite many different attempts and strategies, to consistently measure 450 serum GLP-1 levels in mice in this experiment or other positive control experiments. 451
Thus, we cannot show that the improved health of the animals correlates with increased 452 levels of GLP-1 in vivo and will likely need to move to a larger animal model to address 453 this question. 454
The identification of GspA (PsmD in S. aureus) as the factor responsible for the 455 secretion of GLP-1 allowed us to further investigate how this 25 amino acid peptide 456 impacts cell physiology. Importantly, we have shown that despite only two amino acid 457 differences between GspA and PsmD, these peptides have dramatically different effects 458 on host cell physiology. PsmD, a member of the phenol soluble modulins, has been 459 studied in S. aureus and has many possible roles in host-pathogen interactions, 460 including host colonization (22) . At high levels, PsmD causes lysis of red blood cells and 461 for this reason and has also been described as delta-hemolysin. GspA does not have 462 this activity and indeed, S. epidermidis strains isolated in this study do not possess 463 haemolytic activity as S. aureus does (Supp. Fig 3) . Other functions of GspA, including 464 release of GLP-1 and induction of cytosolic calcium signaling, are not recapitulated by 465
PsmD. Although additional studies are needed, we suspect that the increase in 466 intracellular calcium is linked with release of GLP-1, as calcium is a key regulator of 467 GLP-1 secretion from enteroendocrine cells. 468
Interestingly, during the initial experiments identifying S. epidermidis strains with 469 the ability to stimulate the secretion of GLP-1 in vitro, we also identified two strains of S. 470 epidermidis without stimulatory activity, and without GspA detectable by mass 471 spectrometry. By whole genome sequencing and comparative analysis of two GLP-1 472 stimulatory and two GLP-1 neutral S. epidermidis strains, we demonstrated that the 473 gspA gene is present and homologous in all of the sequenced S. epidermidis strains, 474 regardless of GLP-1 stimulatory activity. However, we identified a single nucleotide 475 polymorphism (SNP) (Supp. Fig 4) in the agrA gene of the neutral strains. AgrA is part 476 of an autoregulatory quorum-sensing system that controls the expression of GspA. In S. 477 aureus, a mutation in agrA leads to a loss in hemolytic activity (23), and we hypothesize 478 that the identified SNP in the GLP-1 neutral S. epidermidis strains accounts for the 479 absence of GspA production and thus, GLP-1 stimulatory activity. 480 S. epidermidis is an interesting conundrum for microbiome researchers in that it 481 clearly is a mutualistic organism that provides health benefits for the host including 482 immune regulation and as a barrier to skin pathogens. Indeed, GspA has been directly 483 linked to enhancing the properties of the defensin LL-37 against the skin pathogen 484 Group A Streptococcus (19). However, most of the research conducted on the species 485 has involved its role in pathogenesis, not as a microbial therapeutic. Although the 486 research community should consider the use of non-traditional microbial strains as 487 therapeutics, with proper safety characterization of course, future studies may aim to 488 develop GspA as a peptide-therapeutic, independent of S. epidermidis. Added microbial 489 therapeutic potential may exist in the expression of gspA in an organism like 490 of GspA on intracellular calcium flux using HEK 293 GCaMP6S cells exposed to GspA 604 and S. aureus PsmD demonstrates greater intracellular calcium levels in cells exposed 605
Figure legends
to GspA. (B) Quantification of calcium flux in the HEK 293 GCaMP6S cells confirms 606 these results. (C) Patch clamp of NCI H716 cells exposed to GspA undergo significant 607 cell depolarization as compared to those exposed to PsmD control peptide (**p < 0.01). 608 609 Figure 7 : GspA exposure on neurogen-3 transduced human intestinal enteroids 610 demonstrates specificity in its activity. GspA exposure did not lead to a loss of (A) cell 611 viability as determined by a resazurin-based PrestoBlue assay. GspA did enhance the 612 secretion of (B) GLP-1 and (C) serotonin but not (D) glucagon, (E) Peptide-YY, and (F) 613 gastric inhibitory peptide (***p < 0.001). 614
